Results 131 to 140 of about 680,918 (208)

Phase IV clinical trials for the treatment of non-small cell lung carcinoma (NSCLC): A systemic review from 2020-2025. [PDF]

Saudi Med J
Kariri YA, Alqasmi MH, Alqahtani BS.
europepmc   +1 more source

Current and future therapies for small cell lung carcinoma. [PDF]

J Hematol Oncol
Zhai X, Zhang Z, Chen Y, Wu Y, Zhen C, Liu Y, Lin Y, Chen C.   +7 more
europepmc   +1 more source

Small Cell Lung Carcinoma Transformation [PDF]

, 2020
openaire   +1 more source

Mid-ventilation PTV approach for stereotactic ablative body radiotherapy in stage I non-small-cell lung carcinoma: Implementation of a single-system workflow. [PDF]

Tech Innov Patient Support Radiat Oncol
Shields-Dowton K, Poder J, Yuen J, Schmidt L, Chin YS.   +4 more
europepmc   +1 more source

Advanced Lung Small Cell Carcinoma [PDF]

, 2020
openaire   +1 more source

Transformation to Neuroendocrine Phenotype in Non-Small-Cell Lung Carcinoma: A Literature Review. [PDF]

Int J Mol Sci
Hernández de Córdoba I, Mielgo-Rubio X, Cejas P, Palomar Ramos J, Garrido-Rubiales B, Falagán Martínez S, Rubio Romero G, Morales Parga M, Moll Taltavull L, Fernández González A, Casado Sáenz E, Sereno M.   +11 more
europepmc   +1 more source

PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation. [PDF]

Front Cell Dev Biol
Grdović N, Tolić A, Jovanović M, Rajić J, Đorđević M, Stojanović M, Hadžić SM, Marković T, Sarić A, Dinić S, Arambašić Jovanović J, Mihailović M, Podolski-Renić A, Pešić M, Vidaković M, Uskoković A.   +15 more
europepmc   +1 more source

Klinefelter syndrome diagnosed at autopsy and small-cell lung carcinoma. [PDF]

Respir Med Case Rep
Sakuranaka H, Tanaka R, Yamakawa Y, Yamada S, Igei K, Asai Y.   +5 more
europepmc   +1 more source

Evaluation of immune microenvironment in non-small cell lung carcinoma after neoadjuvant immunotherapy: a case report. [PDF]

Int J Clin Exp Pathol
Leopizzi M, Pernazza A, Rullo E, Cerbelli B, Pisano A, Anile M, Gelibter A, Rughetti A, Bassi M, Nuti M, d'Amati G, Napoletano C.   +11 more
europepmc   +1 more source

NF-κB activation as a pro-survival signal from pharmacological inhibition of pyruvate dehydrogenase kinase 1 in non-small-cell lung carcinoma cell models. [PDF]

Transl Oncol
Liu Q, Ran M, Shan W, Zhang SL, Tam KY.
europepmc   +1 more source